Table 3. Clinical outcomes stratified by survivor group.
| Parameter | Category/statistics | STS (n=757) | LTS (n=244) | All treated patients (N=1001) |
|---|---|---|---|---|
| Number of deaths | n (%) | 494 (65.3) | 37 (15.2) | 531 (53.0) |
| Due to progression | 458 (92.7) | 34 (91.9) | 492 (92.7) | |
| |
Other |
36 (7.3) |
3 (8.1) |
39 (7.3) |
| PFS since metastatic diagnosis (months) |
Median (95% CI) |
7.3 (6.8–8.0) |
37.2 (32.9–40.5) |
10.2 (9.4–11.0) |
| Number of patients with first progression of disease |
n (%) |
692 (91.4) |
124 (50.8) |
816 (81.5) |
| OS since metastatic diagnosis (months) |
Median (95% CI) |
27.2 (25.4–29.3) |
NE |
35.9 (32.8–39.5) |
|
Best first-line response,
n
(%) | ||||
| CR | 2 (0.3) | 173 (70.9) | 175 (17.5) | |
| PR/SD | 520 (68.7) | 70 (28.7) | 590 (58.9) | |
| Unable to evaluate | 20 (2.6) | 1 (0.4) | 21 (2.1) | |
| |
No assessment |
215 (28.4) |
0 |
215 (21.5) |
| Time between CR and MBC diagnosis,n (%) |
|
n=2 |
n=173 |
n=175 |
| ⩽6 months | 2 (100.0) | 69 (39.9) | 71 (40.6) | |
| 6 to⩽12 months | 0 | 52 (30.1) | 52 (29.7) | |
| 12 to⩽18 months | 0 | 22 (12.7) | 22 (12.6) | |
| 18 to⩽24 months | 0 | 14 (8.1) | 14 (8.0) | |
| |
>24 months |
0 |
16 (9.2) |
16 (9.1) |
| Time between CR/PR/SD and MBC diagnosis, n (%) |
|
n=522 |
n=243 |
n=765 |
| ⩽6 months | 475 (91.0) | 128 (52.7) | 603 (78.8) | |
| 6 to⩽12 months | 45 (8.6) | 59 (24.3) | 104 (13.6) | |
| 12 to⩽18 months | 2 (0.4) | 23 (9.5) | 25 (3.3) | |
| 18 to⩽24 months | 0 | 14 (5.8) | 14 (1.8) | |
| >24 months | 0 | 19 (7.8) | 19 (2.5) | |
Abbreviations: CI=confidence interval; CR=complete response; LTS=long-term survivors; MBC=metastatic breast cancer; NE=non-estimable; OS=overall survival; PFS=progression-free survival; PR, partial response; SD=stable disease; STS=short-term survivors.